Stocks to buy

As we come closer to the end of the year, investors are hoping for a respite from the bear market. With the economy struggling with the highest inflation numbers seen in decades and rising interest rates, 2022 has been a terrible year. Included among the most damaged have been Reddit stocks. The good news is experts predict that the
0 Comments
Although the concept of stocks to buy at the ‘midterm elections’ bottom seems farfetched considering the broader volatility this year, the calendar might provide a change of heart. According to The New York Times, the U.S. equities sector generally follows election-related patterns. “The months leading up to midterm elections have generally been the worst in
0 Comments
Everyone defines “boring stocks” differently, and everyone has their own ideas about criteria for the best boring stocks.  For example, I consider Mexican cement producer Cemex to be an incredibly dull stock. However, if you are in the construction industry, Cemex’s products aren’t dull; actually, they’re vital to your livelihood and well-being. So rather than
0 Comments
[Editor’s note: “The Next Great Tech Bull Market Has Begun” was previously published in September 2022. It has since been updated to include the most relevant information available.] The tech sector dropped like a stone this year. So, it’s easy to forget the cardinal rule that marks many a bull market: Tech still rules the
0 Comments
Any discussion regarding the best dividend stocks of all time begins and ends with the Dividend Aristocrats. They are S&P 500 companies that have increased their annual dividend payment for at least 25 consecutive years. There are currently 65 names on this prestigious list. While there is no question the 65 Dividend Aristocrats have staying power,
0 Comments
Before discussing stocks that will make you a millionaire, there is an important observation to discuss. One of the biggest changes in investing style over the decades is the average holding period. Back in the 1950s, the average holding period for stocks was eight years. Data from June 2020 indicates that the average holding period has
0 Comments
The S&P 500 has been in bear-market territory for more than a month, but it is breaking higher this week. We think there is reason to hope the trend will continue. The first sign of hope is traders have reduced their leverage and margin debt has returned to a more sustainable level. Traders (you included)
0 Comments
As Halloween approaches, investors’ minds may be on finding treats rather than picking stocks. That said, as we head into November, compiling a list of top stock picks to consider is certainly a good move, as many tech stocks have gotten hit very hard. This earnings season hasn’t been kind to many tech stocks. Accordingly,
0 Comments
Not everyone, it seems, is massively bullish about China-based electric vehicle manufacturer Nio (NYSE:NIO). For instance, Tesla (NASDAQ:TSLA) CEO Elon Musk and some analysts with Morgan Stanley might feel cautious about China’s economy and its impact on future automotive sales. But regardless of what they say, it’s not too late to buy NIO stock. The company could
0 Comments
It’s true that the troika of Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), and Meta (NASDAQ:META), much loved by the Street for the decade that ended in mid-2021, reported disappointing third-quarter results. Once viewed as beyond reproach by most, those three stocks are now being shunned and scorned by the “smart money.” But the Street is finally
0 Comments
Safe stocks for retirement are those that are less inclined to suffer in times of turmoil or represent a sector that is more recession-proof than others. That’s not to say that a safe stock will never see a decline – but safe stocks for retirement are more likely to withstand the negative pressures in a
0 Comments
It’s just one piece of positive news after another for Illinois-headquartered pharmaceutical businesses AbbVie (NYSE:ABBV) stock. For one thing, ABBV stock deserves a higher re-rating as the company recently disclosed regulatory victories in the U.S. as well as in Canada. Furthermore, AbbVie finalized its buyout of an immunology specialist, and this will likely provide a significant
0 Comments